Skip to main content

Alzheimer's Awareness Month 2018

New Content ItemEvery three seconds someone develops dementia. 

World Alzheimer's Month, culminating in World Alzheimer's Day on September 21st, looks to create awareness of the global impact of dementia. Alzheimer's Disease & Therapy, the official journal of Alzheimer's Disease International, is proud to provide the research community with the latest open access articles helping the fight against this neurodegenerative disease. Read our latest research, alongside research from other relevant journals from across our portfolio.

Featured Series: Resilience in Dementia

New Content Item © Wikimedia CommonsBrain resilience is the process of adapting well in the face of significant sources of stress, such as Alzheimer’s disease pathology, other neurodegenerative conditions or biological aging.  This thematic series provides a comprehensive overview of what factors contribute to brain resilience and how this affects brain health and cognitive function.

Read the articles

Publication: Ongoing but closed for submissions

Alzheimer's Research & Therapy

Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer’s disease dementia in mild cognitive impairment

Cerebrospinal fluid (CSF) biomarkers have been used to increase the evidence of underlying Alzheimer’s disease (AD) pathology in mild cognitive impairment (MCI). However, CSF biomarker-based classification often results in conflicting profiles with controversial prognostic value. Normalization of the CSF Aβ42 concentration to the level of total amyloid beta (Aβ), using the Aβ42/40 ratio, has been shown to improve the distinction between AD and non-AD dementia. Therefore, we evaluated whether the Aβ42/40 ratio would improve MCI categorization and more accurately predict progression to AD.

Read more

Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic

Cerebrospinal fluid (CSF) biomarkers are increasingly being used to support a diagnosis of Alzheimer’s disease (AD). Their clinical utility for differentiating AD from non-AD neurodegenerative dementias, such as dementia with Lewy bodies (DLB) or frontotemporal dementia (FTD), is less well established. We aimed to determine the diagnostic utility of an extended panel of CSF biomarkers to differentiate AD from a range of other neurodegenerative dementias.

Read more

Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer’s disease

Neuroinflammation has gained increasing attention as a potential contributing factor in Alzheimer’s disease (AD) pathology. A clinical cerebrospinal fluid biomarker capable of monitoring this process during the course of the disease has yet to emerge, chiefly owing to contradictory research findings. In this study, we sought to clarify the utility of inflammatory biomarkers in diagnostic procedures of AD.

Read more

Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease

A growing body of evidence suggests that the plasma concentration of the neurofilament light chain (NfL) might be considered a plasma biomarker for the screening of neurodegeneration in Alzheimer’s disease (AD).

Read more

More Featured Articles